Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$2.34 USD
+0.04 (1.74%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $2.35 +0.01 (0.43%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CKPT 2.34 +0.04(1.74%)
Will CKPT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CKPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CKPT
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock
CKPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CKPT
Buy Rating Justified by Promising Efficacy of Checkpoint’s Cosibelimab in Clinical Trials
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Checkpoint Therapeutics announces presentation of data on cosibelimab
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success